MGP
AXSM icon

M&G plc’s Axsome Therapeutics AXSM Stock Holding History

M&G plc’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Sell
58,976
-32,363
-35% -$7.02M 0.07% 174
2026
Q1 		$15.4M Buy
91,339
+1,011
+1% +$175K 0.08% 149
2025
Q4 		$16.5M Buy
+90,328
New +$12.6M 0.08% 143

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

M&G plc's AXSM Position: Q2 2026 in Review

M&G plc reduced its Axsome Therapeutics (AXSM) stake by 35% in Q2 2026, selling an estimated $7.02M and leaving 58,976 shares worth $14.4M. The position accounts for 0.07% of the portfolio, ranked #174.

M&G plc first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. The position peaked at $16.5M in Q4 2025. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • M&G plc held 58,976 shares of Axsome Therapeutics worth $14.4M as of Q2 2026.
  • M&G plc sold 32,363 Axsome Therapeutics shares in Q2 2026, an estimated $7.02M.
  • Axsome Therapeutics made up 0.07% of M&G plc's portfolio in Q2 2026, its #174 holding.
  • M&G plc first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • M&G plc's Axsome Therapeutics position peaked at $16.5M in Q4 2025.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on M&G plc's 13F filing for Q2 2026, filed 6 Aug 2026.